ADC Therapeutics Revenue Climbs 32.9% to $21 Million in Third Quarter

ADC Therapeutics SA posted $21 million in third-quarter 2026 revenue, up 32.9% from a year earlier and $1.93 million above estimates, while recording a non-GAAP loss of $0.06 per share.

The 32.9% increase compares revenue with the year-earlier quarter. The $1.93 million beat compares it with estimates for the latest quarter.

ADC Therapeutics shares trade on the New York Stock Exchange under the ticker ADCT. Non-GAAP earnings per share is calculated using the company's own methodology.